DBVT News and Press, DBV Technologies S.A. From 05/04/22

Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $ 15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “C...

3 Hot Penny Stocks to Add to Your Watchlist Right Now Recently, we’ve seen major volatility with both penny stocks and blue chips. While volatility can be used as an advantage, for those without a well-thought-out trading strategy, it can be detrimental. If you’re inte...

DBV Technologies S.A. (DBVT) Q1 2022 Results Conference Call May 02, 2022 05:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben - JMP Securities Presentation Operator Welcome to the DBV Technologies First Quarter 2022 Earning...

Montrouge, France, May 2, 2022 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological company, ...

DBV Technologies press release (NASDAQ:DBVT): Q1 GAAP EPS of -$0.30 beats by $0.10. Revenue of $2.55M (-13.3% Y/Y) beats by $1.27M. For further details see: DBV Technologies GAAP EPS of -$0.30 beats by $0.10, revenue of $2.55M beats by $1.27M

Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol ...

AGNC, AMKR, AMRC, ANET, AWR, BGCP, BIGC, BRX, BSM, BXP, CACC, CAR, CBT, CC, CDLX, CHGG, CLX, CSR, CTRA, CVI, DBVT, OTCPK:DOCRF, DVN, DZSI, EARN, EVER, EXPE, FANG, FLS, FMC, FN, FRPT, GAIA, HLIT, HVT, IPI, LEG, LOGI, MED, OTCPK:MEGEF, MGM, MOS, MPWR, MWA, NE, NTR, NXPI, OHI, ORA, OTTR, OUT, PS...

Montrouge, France, April 26, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Montrouge, France, April 25, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Montrouge, France, April 21, 2022 Ordinary and Extraordinary General Meeting of May 12 , 2022 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DB...